Animal Health
Biotech
GMP
Intellectual Property
Legal
Management Skills
Medical Devices
Pharma online
Pharmaceutical
Support Staff

Sponsoring & Exhibiting

For sponsorship and exhibition opportunities at Management Forum events click here

Event Management

To find out about event management click here

Speaking Opportunities

Speaking opportunities are available on selected Management Forum events, please contact us for further information

Management Forum Brochure

Download our catalogue here

Pharmaceutical

A Practical Guide to Writing Risk Management Plans (RMPS)

29 Jan 2018

GBP EUR USD
Standard 699 979 1090
Early 599 839 934
Excluding VAT @ 20.00%

Book by 15 Dec to get the early booking price shown above.

Venue: Rembrandt Hotel, London

Enrol now

Select currency when checking out

4 Jul 2018

GBP EUR USD
Standard 699 979 1090
Excluding VAT @ 20.00%

Venue not yet confirmed

Enrol now

Select currency when checking out

Bespoke training

We can customise this course to meet the requirements of your organisation.

Learn more

Course Overview

Topics to be covered will include:-

  • An Introduction to ICH & EU RMPs – Production & Maintenance
  • Documentation to be Supplied to Regulatory Authorities – the process for RMPs
  • The EU Templates & their Completion – Generic and Innovator Products
  • RMPs in other Countries
  • Practical – Completion of Sections I – III
  • Practical – Completion of Sections IV – VI
  • Practical – Completion of Annexes

Why you should attend

The new Pharmacovigilance Legislation of 2012 now requires companies to provide Risk Management Plans (RMPs) and assessments for all new products whether those products are generic products or new chemical entities. If these are not done correctly this can delay both licensure and sales and damage the Company ability to maximise its products. Maintenance of the RMPs also is an important aspect for maintaining the licence, compliance and these are reviewed in Regulatory Inspections. Can you afford not to get this right?

Who should attend

This course will be relevant for anyone requiring a comprehensive overview of the Pharmacovigilance function and duties. It may be of particular interest to those who are responsible in Pharmacovigilance for any safety assessments and writing such plans including any Medical Directors who approve such plans. Those who work with pharmacovigilance, e.g. Regulatory Affairs, Clinical, Sales & Marketing, Legal, Commercial and Quality and EU QP PVs that must sign off such documents.

Programme

09.00 Registration and Coffee

09.30 Meeting begins

An Introduction to EU RMPs – Production & Maintenance

  • ICH E2E – Risk Management Plans
  • EU Module V – Risk Management Plans
  • Production of the EU RMP
  • Maintenance of the RMP (Safety Reviews; PSURs/DSURs)

Documentation to be Supplied to Regulatory Authorities – the process for RMPs

  • Generic RMPs
  • RMPs for Innovator products
  • Additional documents to supply to the Regulators
  • Safety reporting Timelines for RMPs
  • Japan and the USA and RMPs

The EU Templates & their Completion – Generic and Innovator Products Including RMPs in other Countries

  • The EU Generic template
  • The EU Template for innovator products
  • The RMP Template in Japan

Practical – Completion of Sections I – III

  • Section I – Information sources and completion
  • Section II – Common aspects for Risk appraisal from Clinical Studies
  • Section III – The Pharmacovigilance Plan

Practical – Completion of Sections IV – VI

  • Section IV – Post Authorisation Efficacy Studies
  • Section V – Risk Minimisation Activities
  • Section VI – Summary of the RMP

Practical – Completion of Annexes

  • Annex 1: Interface between RMP and Eudravigilance/EPITT
  • Annex 2: Summary of product characteristics (SmPC) and package leaflet.
  • Annex 3: Worldwide marketing authorisation status by country (including EEA)
  • Annex 4: Synopsis of on-going and completed clinical trial programme
  • Annex 5: Synopsis of on-going and completed pharmacoepidemiological study programme
  • Annex 6: Protocols for proposed and on-going studies
  • Annex 7: Specific adverse event follow-up forms
  • Annex 8: Protocols for proposed and on-going studies in RMP part IV
  • Annex 9: Synopsis of newly available study reports for RMP parts III-IV
  • Annex 10: Details of proposed additional risk minimisation activities (if applicable)
  • Annex 11: Mock up examples of the material provided to healthcare professionals and patients
  • Annex 12: Other supporting data (including referenced material)

17.00 Meeting ends

Presenter

Graeme Ladds

Graeme Ladds, Director of PharSafer, has over 26 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

You may also be interested in...

How to Write Effective SOPs

Improving Processes and CAPA (Corrective and Preventative Action)

A Practical Guide to Producing and Maintaining the PSMF

An Introduction to Risk Evaluation & Mitigation Strategies (REMS)

Previous customers include...

  • Alfa Wassermann S.p.A.
  • A Nelson & Co Ltd
  • Alfrapharma Srl
  • Cmed
  • Colgate-Palmolive R&D
  • Conforma NV
  • DBV Technologies
  • ELPEN Pharmaceutical Co Inc
  • Emtex BVBA
  • Ewopharma International s.r.o
  • FAES FARMA SA
  • GRUPO FERRER INTERNACIONAL SA
  • Icon Clinical Research (UK) Limited
  • Iggea Ltd
  • IRE-TEX INNOVATIONS LTD
  • Jacobsen Pharma & MedTech Advice A/S
  • JensonR+ Ltd
  • Kem Pharmaceuticals Limited
  • Mapi Life Sciences Canada Inc.
  • Medac GmbH
  • Mediplex Ltd
  • NDA Regulatory Science Ltd
  • Norgine Ltd
  • Pharmacovigilance Matters Limited
  • ProductLife
  • Recordati
  • Red Line Pharmacovigilance
  • VAN Pharma Consult
  • Veterinary Medicines Directorate
  • ZAMBON SPA